Steve Beuchaw
Stock Analyst at Morgan Stanley
(1.56)
# 1,464
Out of 4,650 analysts
104
Total ratings
62.32%
Success rate
6.97%
Average return
Main Sectors:
Stocks Rated by Steve Beuchaw
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QGEN Qiagen | Upgrades: Overweight | $49 → $51 | $43.23 | +17.97% | 1 | Feb 16, 2024 | |
| A Agilent Technologies | Initiates: Outperform | n/a | $133.67 | - | 20 | Dec 13, 2023 | |
| ALGN Align Technology | Maintains: Outperform | $711 → $770 | $219.09 | +251.45% | 11 | Jul 29, 2021 | |
| BRKR Bruker | Upgrades: Peer Perform | n/a | $56.02 | - | 9 | Nov 16, 2020 | |
| HSIC Henry Schein | Upgrades: Outperform | $68 | $67.46 | +0.80% | 4 | Apr 2, 2020 | |
| XRAY DENTSPLY SIRONA | Upgrades: Outperform | $66 | $17.77 | +271.41% | 6 | Apr 2, 2020 | |
| ILMN Illumina | Maintains: Equal-Weight | $320 → $288 | $147.62 | +95.10% | 9 | Jan 7, 2019 | |
| TMO Thermo Fisher | Maintains: Overweight | $254 → $260 | $540.75 | -51.92% | 7 | Oct 25, 2018 | |
| WAT Waters | Maintains: Equal-Weight | $204 → $211 | $385.79 | -45.31% | 13 | Oct 10, 2018 | |
| MYGN Myriad Genetics | Maintains: Overweight | $51 → $54 | $16.17 | +233.95% | 10 | Oct 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $21 → $41 | $135.12 | -69.66% | 5 | Sep 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $335 | $364.53 | -8.10% | 1 | Sep 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $335 | $334.85 | +0.04% | 1 | Sep 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $19 | $20.76 | -8.48% | 5 | Aug 31, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $30,000 → $25,000 | $0.52 | +4,770,892.37% | 2 | Mar 15, 2017 |
Qiagen
Feb 16, 2024
Upgrades: Overweight
Price Target: $49 → $51
Current: $43.23
Upside: +17.97%
Agilent Technologies
Dec 13, 2023
Initiates: Outperform
Price Target: n/a
Current: $133.67
Upside: -
Align Technology
Jul 29, 2021
Maintains: Outperform
Price Target: $711 → $770
Current: $219.09
Upside: +251.45%
Bruker
Nov 16, 2020
Upgrades: Peer Perform
Price Target: n/a
Current: $56.02
Upside: -
Henry Schein
Apr 2, 2020
Upgrades: Outperform
Price Target: $68
Current: $67.46
Upside: +0.80%
DENTSPLY SIRONA
Apr 2, 2020
Upgrades: Outperform
Price Target: $66
Current: $17.77
Upside: +271.41%
Illumina
Jan 7, 2019
Maintains: Equal-Weight
Price Target: $320 → $288
Current: $147.62
Upside: +95.10%
Thermo Fisher
Oct 25, 2018
Maintains: Overweight
Price Target: $254 → $260
Current: $540.75
Upside: -51.92%
Waters
Oct 10, 2018
Maintains: Equal-Weight
Price Target: $204 → $211
Current: $385.79
Upside: -45.31%
Myriad Genetics
Oct 10, 2018
Maintains: Overweight
Price Target: $51 → $54
Current: $16.17
Upside: +233.95%
Sep 28, 2018
Maintains: Overweight
Price Target: $21 → $41
Current: $135.12
Upside: -69.66%
Sep 20, 2018
Initiates: Equal-Weight
Price Target: $335
Current: $364.53
Upside: -8.10%
Sep 20, 2018
Initiates: Equal-Weight
Price Target: $335
Current: $334.85
Upside: +0.04%
Aug 31, 2018
Maintains: Underweight
Price Target: $21 → $19
Current: $20.76
Upside: -8.48%
Mar 15, 2017
Downgrades: Underweight
Price Target: $30,000 → $25,000
Current: $0.52
Upside: +4,770,892.37%